Anti‐VEGF therapy is commonly used as one part of a co‐therapy, so achieving a larger decrease in tumor growth should have necessitated the use of a secondary therapeutic, but since our goal was to only assess the potential of MMP‐activatable PepFects in tumor gene therapy, adding a co‐therapeutic was not optimal. Here, VEGFA is linked to neoplasm.